Web Analytics
top of page


Yale’s Erol Fikrig and Richard Flavell published an article in 1995 that says OspA won't work as a vaccine due to antigenic variation or “antibody selection pressure.”  They own the patent for LYMErix (OspA):

Yale’s Erol Fikrig and Richard Flavell, who own the patent for LYMErix (OspA), also own the only VALID method for diagnosing "Lyme disease" (US Patent 5,618,533), but they did not use this method to evaluate the LYMErix trial victims. 
bottom of page